The SMC has also accepted the drug for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human chorionic gonadotrophin (hCG) therapy.
According to the SMC, follitropin alfa (Bemfola®) has demonstrated clinical equivalence to another follitropin alfa product for stimulation of multi-follicular development for superovulation in ART.